Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call

About this update from Ironwood Pharmaceuticals, Inc.

BOSTON --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 27, 2025 . Individuals interested in participating in the call should dial (888) 596-4144 ( U.S. and Canada ) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com . The call will be available for replay via telephone starting Thursday, February 27, 2025 , at approximately 11:30 a.m. Eastern Time , running through 11:59 p.m. Eastern Time on Thursday, March 13, 2025 . To listen to the replay, dial (800) 770-2030 ( U.S. and Canada ) or (609) 800-9909 (international) using conference ID number 2530602. The archived webcast will be available on Ironwood’s website for 1 year beginning approximately one hour after the call has completed. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients who are dependent on parenteral support. In addition, Ironwood has been a pioneer in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years old. Building upon our history of innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of diseases and address significant unmet needs. Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts , with a site in Basel, Switzerland . We routinely post information that may be important to investors on our website at www.ironwoodpharma.com . In addition, follow us on X and on LinkedIn . View source version on businesswire.com : https://www.businesswire.com/news/home/20250213887685/en/ Company contact: Greg Martini [email protected] Investors: Precision AQ (formerly Stern Investor Relations) Stephanie Ascher [email protected] Source: Ironwood Pharmaceuticals, Inc.

View stock analysis, news, and events for Ironwood Pharmaceuticals, Inc.